Nouveautés 2025 dans le lymphome folliculaire
Hématologie · 01.06.2026 · 32 (S1) · 21-27
DOI: 10.1684/hma.2026.1919 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hématologie, erschienen am 01.06.2026. Verfasst von Clémentine Sarkozy.
Abstract (Originalsprache)
Advances in follicular lymphoma in 2025 were dominated by immunotherapies, including both monospecific antibodies and T cell–engaging therapies, such as bispecific antibodies and chimeric antigen receptor T-cell (CAR T-cell) therapy. In the relapsed/refractory setting from the second line onward, two phase III trials (EPCORE FL-1 and inMIND) showed that new combinations adding epcoritamab or tafasitamab to rituximab plus lenalidomide (R2) were significantly superior to R2 alone, paving the way for new second-line standards, although their toxicity profiles will need to be monitored. In the third line or beyond, CAR T-cell therapies have confirmed deep and durable responses, with a plateau in progression-free survival, suggesting a possible paradigm shift toward cure. In first-line treatment, bispecific antibodies, alone or in combination, have shown high response rates, although further follow-up is needed to assess the durability of these responses. Phase III trials comparing this approach with anti-CD20 antibody plus chemotherapy are ongoing. Finally, a new score, FLIPI24, appears to improve prognostic stratification, helping to identify patients at high risk of early relapse so that management can be adapted and clinical trials developed.
Zitieren
APA
Sarkozy, C. (2026). Nouveautés 2025 dans le lymphome folliculaire. Hématologie, 32(S1), 21-27. https://doi.org/10.1684/hma.2026.1919
Vancouver
Sarkozy C. Nouveautés 2025 dans le lymphome folliculaire. Hématologie. 2026;32(S1):21-27. doi:10.1684/hma.2026.1919
BibTeX
@article{Sarkozy2026,
author = {Sarkozy, Clémentine},
title = {Nouveautés 2025 dans le lymphome folliculaire},
journal = {Hématologie},
year = {2026},
volume = {32},
number = {S1},
pages = {21--27},
doi = {10.1684/hma.2026.1919}
}
EUVIMED